To support CStone’s development of sugemalimab, a potential best-in-class PD-L1 antibody being developed for high-incidence cancer indications in China.
Will accelerate the commercialization of Koligo’s KYSLECEL, a personalized islet cell therapy available in the U.S. for chronic and recurrent acute pancreatitis